Collegium Pharmaceutical (NasdaqGS:COLL) M&A announcement Transcript

Summary of Collegium Pharmaceutical Investor Call Company Overview - Company: Collegium Pharmaceutical (NasdaqGS:COLL) - Event: Investor Call regarding the acquisition of AZSTARYS from Corium Therapeutics - Date: March 19, 2026 Key Points Acquisition Details - Collegium announced the acquisition of AZSTARYS and relevant subsidiaries from Corium Therapeutics for $650 million in cash, with potential contingent payments of up to $135 million based on sales and regulatory milestones [8][10][19] - The acquisition is expected to close in the second quarter of 2026 [19] Strategic Rationale - The acquisition significantly expands Collegium's position in the ADHD market, adding a second differentiated treatment alongside Jornay PM [5][19] - AZSTARYS is expected to extend ADHD revenues into 2037, five years beyond Jornay PM's expected loss of exclusivity [7][19] - The deal is aligned with Collegium's capital allocation strategy, balancing portfolio expansion and fiscal responsibility [8][19] Financial Impact - The acquisition is projected to be immediately accretive to adjusted EBITDA, with AZSTARYS expected to generate over $50 million in pro forma net revenues in the second half of 2026 [10][11] - Collegium generated over $329 million in cash from operations in 2025, indicating strong cash flow to support the acquisition [9] Market Context - The ADHD market is large and growing, with approximately 22 million patients in the U.S. and 111 million prescriptions written in 2025 [12] - ADHD prescriptions have been growing at about 8% annually over the past five years, with 90% of prescriptions for stimulant medications [12] Product Differentiation - Jornay PM is unique as it is taken at night and provides efficacy upon awakening, while AZSTARYS combines fast and long-acting medications in one capsule [15][17] - Both products target different patient needs, with Jornay PM primarily used in children and adolescents, and AZSTARYS having a more balanced distribution between adults and children [17][18] Sales and Marketing Strategy - Collegium plans to leverage its existing ADHD commercial infrastructure to drive growth for both products, expecting significant cost synergies of over $50 million within 12 months post-acquisition [10][19] - The company has a sales force of 180 representatives, compared to Corium's 100, which will enhance marketing efforts for AZSTARYS [30][37] Future Outlook - Collegium remains open to further acquisitions in both ADHD and potentially other therapeutic areas, maintaining a focus on capital-efficient opportunities [50][51] - The company aims to maximize the potential of both Jornay PM and AZSTARYS, ensuring broad access and support for the ADHD community [45][54] Additional Insights - Healthcare professionals have rated both Jornay PM and AZSTARYS highly, with 70% indicating a strong intent to increase prescribing of Jornay PM and 53% for AZSTARYS [15][16] - The acquisition reflects Collegium's commitment to innovation and financial discipline, aiming to create long-term shareholder value [19][21] Conclusion - The acquisition of AZSTARYS is a strategic move for Collegium, enhancing its ADHD portfolio and positioning the company for sustained growth and shareholder value creation in the biopharmaceutical sector [21][64]